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δ-­catenin  is  a  crucial  component  of  a  synaptic  scaffolding  complex,  which  regulates  synaptic  
structure  and  function  in  neurons.  Loss  of  δ-­catenin  function  is  strongly  associated  with  severe  
autism  spectrum  disorder  (ASD)  in  female-­enriched  multiple  families.  In  particular,  a  G34S  
(Glycine  34  to  Serine)  mutation  in  the  δ-­catenin  gene  has  been  identified  in  ASD  patients  and  
suggested  to  exhibit  loss-­of-­function.  The  G34S  mutation  is  located  in  the  amino  terminal  region  
of  δ-­catenin,  where  there  are  no  known  protein  interaction  domains  and  post-­translational  
modifications.  Notably,  the  Group-­based  Prediction  System  predicts  that  the  G34S  mutation  is  
an  additional  target  for  GSK3β-­mediated  phosphorylation,  which  may  result  in  protein  
degradation.  Therefore,  we  hypothesize  the  G34S  mutation  accelerates  δ-­catenin  degradation,  
resulting  in  loss  of  δ-­catenin  function  in  ASD.  Indeed,  we  found  significantly  lower  G34S  δ-­
catenin  levels  compared  to  wild-­type  (WT)  δ-­catenin  when  expressed  in  cells  lacking  
endogenous  δ-­catenin,  which  is  rescued  by  genetic  inhibition  of  GSK3β.  By  using  Ca2+  imaging  
in  cultured  mouse  hippocampal  neurons,  we  further  revealed  overexpression  of  WT  δ-­catenin  is  
able  to  significantly  increase  neuronal  Ca2+  activity.  Conversely,  Ca2+  activity  remains  unaffected  
in  G34S  δ-­catenin  overexpression,  which  is  reversed  by  pharmacological  inhibition  of  GSK3β  
using  lithium.  This  suggests  the  G34S  mutation  of  δ-­catenin  provides  an  additional  GSK3β-­
mediated  phosphorylation  site,  which  could  promote  δ-­catenin  premature  degradation,  resulting  
in  loss-­of-­function  effects  on  neuronal  Ca2+  activity  in  ASD.  In  addition,  inhibition  of  GSK3β  
activity  is  able  to  reverse  G34S-­induced  loss  of  δ-­catenin  function.  Thus,  inhibition  of  GSK3β  
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   Autism  spectrum  disorder  (ASD)  is  a  multifactorial  neurodevelopmental  disorder  that  
begins  early  in  life  and  is  highly  heterogeneous  in  symptom  presentation  and  etiology  (1,  2).  
Restricted  and  repetitive  behavior  and  impairment  in  sociability  and  communication  are  the  two  
characteristics  present  to  be  diagnosed  as  ASD,  but  the  broad  range  of  the  symptom  severity  
may  be  minor  to  intense  (1).  Thus,  the  characterization  of  ASD  is  difficult  due  to  the  high  
comorbidity,  as  presentation  of  other  psychiatric  diagnoses  is  common  in  ASD  such  as  Attention  
Deficit  and  Hyperactivity  Disorder  (ADHD),  anxiety,  depression,  and  intellectual  disability  (1).  
Importantly,  there  are  a  large  number  of  the  ASD-­risk  genes  identified  from  various  genetic  
studies  that  are  involved  with  synaptic  activity  and  plasticity  (3-­8).  This  suggests  that  ASD  may  
result  from  deficits  occurring  in  the  synapse.  Significantly,  the  δ-­catenin  gene  is  associated  with  
severe  autism  in  female-­enriched  multiple  families  (2-­4).  It  has  also  been  found  to  have  more  
deleterious  variants,  copy  number  variations  (CNVs),  and  de  novo  mutations  associated  with  
ASD  (2,  5).  Some  of  the  ASD-­associated  δ-­catenin  missense  mutations  are  unable  to  rescue  
loss  of  excitatory  synapse  density  in  hippocampal  neurons  lacking  the  δ-­catenin  gene,  
suggesting  these  δ-­catenin  mutations  induce  loss-­of-­function  (2).  However,  the  cellular  
mechanisms  of  how  ASD  mutations  cause  loss  of  δ-­catenin  function  in  the  synapse  remain  
unclear.    
δ-­catenin  is  an  armadillo  repeat  protein  that  is  highly  prevalent  in  the  brain  (6).  It  is  able  
to  adhere  to  the  intracellular  side  of  the  postsynaptic  membrane  by  its  armadillo-­repeat  
interaction  domain  with  N-­cadherin,  a  synaptic  cell-­adhesion  protein  (7,  8)  (Fig.  1).  In  addition,  
the  PDZ-­binding  domain  located  in  the  δ-­catenin  carboxyl-­terminal  end  is  able  to  connect  to  a  
glutamate  receptor  interacting  protein  (GRIP)  and  a-­amino-­3-­hydroxy-­5-­methyl-­4-­
isoxazolepropionic  acid  receptor  (AMPAR)-­binding  protein  (ABP)  (8-­11)  (Fig.  1).  The  resulting  




Figure  1.  A  schematic  of  N-­cadherin-­δ-­catenin-­ABP/GRIP-­GluA2  synaptic  complex  and  
GSK3b  regulation  of  δ-­catenin.  The  AMPAR  GluA2  subunit  is  tethered  to  the  synaptic  
membrane  by  its  carboxyl-­tail  interaction  with  the  GRIP/ABP’s  PDZ  domain.  δ-­catenin  scaffolds  
to  N-­cadherin  and  GRIP/ABP  by  binding  to  another  of  GRIP/ABP’s  PDZ  domain  located  in  
amino-­terminal  region.  GSK3β  phosphorylates  δ-­catenin,  which  leads  to  δ-­catenin  degradation.    
Pharmacological  or  genetic  reduction  of  GSK3β  activity  by  lithium  or  siRNA  stabilizes  N-­
cadherin-­δ-­catenin-­ABP/GRIP-­GluA2  complex.  
  
subunit  GluA2  (10)  (Fig.  1),  suggesting  δ-­catenin  plays  crucial  roles  in  synaptic  structure  and  
function.  In  fact,  δ-­catenin  homozygous  knockout  (KO)  mice  show  deficits  of  hippocampus-­
dependent  learning  and  memory  with  disrupted  short  and  long-­term  synaptic  plasticity  in  the  
hippocampus  (12).  δ-­catenin  KO  mice  also  exhibit  a  decrease  in  dendritic  arbor  size,  segment  
number,  tip  number,  and  branching  complexity  with  reduced  levels  of  N-­cadherin  and  GluA2  
(12-­14).  Knockdown  of  δ-­catenin  by  shRNA  in  cultured  rat  pyramidal  neurons  is  accompanied  
by  reduction  of  spine  head  width  and  length  (11),  which  further  supports  that  δ-­catenin  is  
important  in  spine  architecture  and  synaptic  plasticity.    
Notably,  there  are  genetic  links  between  δ-­catenin  and  other  neurological  disorders.  For  
example,  a  yeast-­two-­hybrid  experiment  reveals  δ-­catenin’s  interaction  with  the  Alzheimer’s  
disease-­related  protein  presenilin  1,  affecting  senile  plaque  formation,  a  pathological  hallmark  in  
the  disease  (15,  16).  Epilepsy  is  commonly  associated  with  ASD  occurring  in  about  one  third  of  
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ASD  individuals  (17),  and  loss  of  δ-­catenin  function  is  also  linked  to  familial  cortical  myoclonic  
tremor  and  epilepsy  (FCMTE)  (18).  Furthermore,  Cri-­du-­chat  syndrome  is  a  
neurodevelopmental  disorder  associated  with  variable  hemizygous  deletions  in  the  short  arm  of  
human  chromosome  5p  where  the  δ-­catenin  gene  is  located  (19).  Symptoms  of  Cri-­du-­chat  
syndrome  include  delayed  development,  severe  mental  retardation,  and  verbal  skill  impairment  
(20).  About  40%  of  individuals  with  the  syndrome  exhibit  autistic-­like  behaviors  (21).  Importantly,  
genetics  studies  of  Cri-­du-­chat  syndrome  and  ASD  both  identify  loss  of  δ-­catenin  function  (3,  
22).  Moreover,  δ-­catenin-­associated  proteins  have  been  found  to  be  associated  with  ASD  (23,  
24),  including  N-­cadherin  (25),  GRIP  (26),  and  AMPARs  (27),  which  further  implicates  crucial  
roles  of  δ-­catenin  in  the  etiology  of  ASD.  This  suggests  loss  of  δ-­catenin  function  may  be  a  
strong  candidate  for  ASD  pathophysiology.  
   Glycogen  synthase  kinase  3  beta  (GSK3β)  is  a  serine/threonine  kinase  that  plays  an  
important  role  in  many  cellular  processes  (28).  For  instance,  GSK3β  is  a  key  regulator  of  
synaptic  plasticity  with  involvement  in  N-­methyl-­D-­aspartate  receptor  (NMDAR)-­dependent  long-­  
term  depression  (LTD)  and  long-­term  potentiation  (LTP)  (29).  Notably,  GSK3β  regulates  the  
stability  of  the  armadillo-­repeat  protein  family  members,  including  β-­catenin,  p120-­catenin  and  
δ-­catenin  (30-­32).  In  particular,  regulation  of  β-­catenin  has  been  extensively  studied.  β-­catenin  
turnover  is  initiated  through  a  multiple  protein  complex  called  the  β-­catenin  destruction  complex,  
which  consists  of  the  scaffolding  protein  Axin,  adenomatous  polyposis  coli  (APC),  casein  kinase  
I-­alpha  (CKIa),  and  GSK3β  (33,  34).  CKIa  performs  the  first  priming  phosphorylation  on  β-­
catenin  residue  serine  45  (S45),  which  triggers  subsequent  β-­catenin  phosphorylation  by  
GSK3β  on  β-­catenin  residues  serine  33  and  37  (S33  and  S37)  and  threonine  41  (T41)  to  target  
β-­catenin  for  ubiquitination  and  subsequent  proteasomal  degradation  (30,  35).  Importantly,  
recent  studies  suggest  that  changes  in  GSK3β  activity  may  be  an  important  aspect  of  ASD  
pathogenesis  (36-­43).  However,  extensive  studies  have  yielded  inconsistent  data  on  the  role  of  
GSK3β  activity  in  the  molecular  and  behavioral  effects.  For  example,  elevated  GSK3β  activity  is  
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responsible  for  the  ASD-­related  phenotypes  in  the  mouse  model  of  fragile  X  mental  retardation  
(FMR)  (36-­39).  Conversely,  inactivation  of  GSK3β  is  associated  with  the  ASD-­related  
phenotypes  found  in  deletion  of  the  phosphatase  and  tensin  homolog  on  chromosome  ten  
(PTEN)  gene  in  mice  (40).  Therefore,  further  studies  are  needed  in  order  to  better  understand  
the  roles  of  GSK3β  in  ASD  pathogenesis.  Nonetheless,  GSK3β  inhibitors  may  be  useful  
therapeutic  interventions  for  brain  disorders  because  GSK3β  has  been  linked  to  cognitive  
processes  (44).  Pharmacological  inhibition  of  GSK3β  can  occur  by  lithium  treatment,  which  can  
reduce  GSK3β  activity  by  increasing  the  Akt-­dependent  phosphorylation  of  the  autoinhibitory  
serine  9  on  GSK3β  (45)  or  by  being  a  competitive  inhibitor  with  respect  to  magnesium  binding  to  
GSK3β  (44).  Reduction  of  GSK3β  activity  by  lithium  in  hippocampal  neurons  in  vitro  and  in  vivo  
is  able  to  increase  levels  of  β-­catenin,  δ-­catenin,  and  δ-­catenin-­associated  synaptic  complex  
proteins  including  GRIP  and  AMPARs,  which  supports  the  findings  of  increased  amplitude  of  
miniature  excitatory  postsynaptic  currents  (EPSCs)  when  lithium  treatment  was  applied  to  
neurons  (46).  Therefore,  an  increase  in  δ-­catenin  at  synapses  by  pharmacological  inhibition  of  
GSK3β  activity  may  provide  a  cellular  mechanism  of  novel  therapeutic  effects  for  loss  of  δ-­
catenin  function  in  ASD.  
One  δ-­catenin  gene  missense  mutation  associated  with  ASD  is  glycine  34  to  serine  
(G34S).  G34S  δ-­catenin  is  unable  to  rescue  the  number  of  excitatory  synapses  in  cultured  
hippocampal  neurons  lacking  δ-­catenin,  thus  exhibiting  loss  of  δ-­catenin  function  (2).  The  
cellular  mechanisms  of  how  G34S  δ-­catenin  induces  loss-­of-­function  are  unknown.  Intriguingly,  
the  amino-­terminal  region  of  δ-­catenin  around  G34  has  not  been  reported  to  contain  major  post-­
translational  modification  sites  or  protein  interaction  domains  (47).  GSK3β-­mediated  
phosphorylation  of  threonine  1078  (T1078)  toward  the  carboxyl  end  in  δ-­catenin  targets  δ-­
catenin  for  ubiquitination  then  proteasome-­mediated  degradation  (35,  48)  (Fig.  2).  Conversely,  
GSK3β  phosphorylates  residues  S33,  S37  and  T41  on  the  amino  terminus  side  in  β-­catenin  (49)  
(Fig.  2).  Similar  to  β-­catenin,  p120-­catenin  has  GSK3β  phosphorylation  sites  in  the  amino  
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terminus,  which  induces  ubiquitination  and  destabilization  of  p120-­catenin  (31).  Importantly,  the  
Group-­Prediction  System  (http://gps.biocuckoo.org)  (50)  predicts  that  the  G34S  mutation  can  be  
a  target  for  GSK3β,  allowing  δ-­catenin  to  have  multiple  serine  residues  in  the  amino-­terminal  
end  that  mimics  GSK3β-­mediated  phosphorylation  of  β-­catenin  (Fig.  2).  In  addition  to  T1078  in  
the  carboxyl-­terminus,  these  potential  sites  for  GSK3β-­mediated  phosphorylation  in  the  amino-­
terminal  region  may  accelerate  δ-­catenin  degradation,  inducing  loss  of  δ-­catenin  function.    
  
Figure  2.  The  δ-­catenin  G34S  mutation  may  add  an  additional  GSK3b-­mediated  
phosphorylation  site  to  induce  degradation.  GSK3β  phosphorylation  sites  of  b-­catenin  in  the  
amino-­terminal  region  known  to  induce  proteasomal  degradation  highlighted  in  red  (S33,  S37,  
and  T41)  are  comparable  to  possible  GSK3β  phosphorylation  sites  in  the  amino-­terminus  of  
G34S  mutant  δ-­catenin  also  highlighted  in  red  (S30,  S34,  and  S38).  In  addition  to  GSK3b  WT  δ-­
catenin  T1078  phosphorylation  site  in  the  carboxyl-­terminus,  these  potential  amino-­terminal  
GSK3β-­mediated  phosphorylation  sites  may  accelerate  δ-­catenin  degradation.  
  
Therefore,  we  hypothesize  that  the  ASD-­associated  G34S  δ-­catenin  mutation  promotes  
premature  degradation  via  GSK3β-­mediated  additional  phosphorylation,  thus  causing  disruption  
of  synaptic  structure  and  function  in  ASD.  Inhibition  of  GSK3β  may  reverse  loss  of  δ-­catenin-­
induced  synaptic  dysfunction  in  ASD.  In  this  study,  we  have  found  significantly  lower  δ-­catenin  
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protein  levels  in  cells  expressing  G34S  δ-­catenin  compared  to  wild-­type  (WT)  δ-­catenin,  which  
is  rescued  by  genetic  knockdown  of  GSK3β.  By  using  Ca2+  imaging  in  cultured  mouse  primary  
hippocampal  neurons,  we  further  revealed  the  overexpression  of  WT  δ-­catenin  is  able  to  
significantly  increase  neuronal  Ca2+  activity,  but  Ca2+  activity  remains  unaffected  in  G34S  δ-­
catenin  overexpression,  indicating  loss  of  δ-­catenin  function.  More  importantly,  G34S  δ-­catenin-­
induced  loss-­of-­function  effects  on  Ca2+  activity  is  reversed  by  pharmacological  inhibition  of  
GSK3β  using  lithium.  Together,  this  data  provides  a  novel  cellular  mechanism  of  ASD  and  
identifies  a  potential  therapeutic  target  for  δ-­catenin-­associated  ASD  patients.  
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   pSinRep5-­WT  δ-­catenin  and  pSinRep5-­G34S  δ-­catenin  plasmids  were  gifts  from  Dr.  
Edward  Ziff  (New  York  University  Langone  Medical  Center).  HA-­tagged  WT  δ-­catenin  and  G34S  
δ-­catenin  were  cloned  into  the  mammalian  expression  vector,  pcDNA3.1.  The  QuikChange  XL  
Site-­Directed  Mutagenesis  Kit  (Agilent)  was  used  to  generate  G34A  and  G34D  mutations  from  
the  WT  δ-­catenin  plasmid.  The  following  primers  were  used  with  the  bolded  regions  being  
where  the  mutations  were  made  to  exchange  the  glycine  (GGC):  G34A  primers  5'-­
gctccttgagcccagccttaaacacctccaa-­3'  and  5'-­ttggaggtgtttaaggctgggctcaaggagc-­3',  and  the  G34D  
primers  5'-­cagctccttgagcccagacttaaacacctccaatg-­3'  and  5'-­
cattggaggtgtttaagtctgggctcaaggagctg-­3'.  
  
Cell  Culture  and  Transfection  
Human  embryonic  kidney  cells  (HEK293)  were  cultured  in  DMEM  L-­Glutamine  medium  
(Life  Technologies)  supplemented  with  10%  fetal  bovine  serum  (FBS)  and  1%  
penicillin/Streptomycin  (Life  Technologies)  with  37oC  humidified  5%  CO2.  500,000  cells  were  
plated  in  6-­well  dishes  and  1µg  of  DNA  was  transfected  when  cells  reached  75-­85%  confluency  
with  Lipofectamine  2000  (Life  Technologies)  according  to  the  manufacturer’s  instructions.  25nM  
control  siRNA  ON-­TARGETplus  Non-­targeting  pool  (Dharmacon)  and  SMARTpool  ON-­
TARGETplus  human  GSK3β  siRNA  (Dharmacon)  were  transfected  with  1µg  of  DNA  when  cells  






Proteasome  inhibitor  MG132  (Allfa  Aesar)  was  used  at  10µM  to  treat  HEK293  cells  1  hr  
after  DNA  transfection  and  incubated  for  16  hrs  before  cell  lysis.  GSK3β  pharmacological  
inhibitor  lithium  chloride  (LiCl)  was  used  at  2mM  to  treat  cultured  hippocampal  neurons  16-­19  
hrs  before  live  Ca2+  imaging  was  performed.    
  
Immunoblotting  
Whole  cell  lysates  (20µl  /100µl  total  cell  lysate)  were  loaded  onto  10%  SDS-­PAGE  gel  
and  subjected  to  electrophoresis  at  a  constant  125V.  Proteins  were  then  transferred  to  
nitrocellulose  membrane  at  20V  for  overnight.  Membranes  were  blocked  with  5%  non-­fat  milk  
and  blotted  with  anti-­δ-­catenin  (BD  Biosciences,  1:1000),  anti-­GSK3β  (Cell  Signaling  
Technology,  1:1000),  and  anti-­actin  (Abcam,  1:2000).  Secondary  antibodies  used  were  goat  
polyclonal  anti-­mouse  antibody  (Abcam,  1:4000)  and  goat  polyclonal  anti-­rabbit  antibody  
(Abcam,  1:4000).  Immunoblots  were  developed  with  Enhanced  Chemiluminescence  (ECL)  
(ThermoScientific).  Blots  were  chosen  in  the  middle  of  a  linear  time  of  exposure  and  quantified  
by  using  NIH  ImageJ.  
  
Hippocampal  Mouse  Neuron  Culture  
The  mouse  hippocampal  neuron  cultures  were  prepared  as  previously  described  (51-­
54).  C57BI6J  mouse  (Jackson  laboratory)  hippocampal  neurons  were  dissected  from  postnatal  
day  0  (P0)  pups.  The  tissue  isolated  was  digested  with  10U/mL  papain  (Worthington  
Biochemical  Corp)  for  15  mins  and  resuspended  in  DMEM/F12  Medium  (Life  Technologies)  
containing  5%  Horse  Serum,  5%  FBS,  1.5%  HEPES,  and  1%  penicillin/streptomycin  (Life  
Technologies).  500,000  cells  were  plated  on  poly  lysine-­coated  glass  bottom  dishes  
(Matsunami)  for  1.5  hrs  in  the  DMEM/F12  medium  in  a  37oC  humidified  5%  CO2  incubator.  The  
medium  was  then  exchanged  with  Neurobasal  Medium  (Life  Technologies),  0.5mM  Glutamax  
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(Life  Technologies),  B27  supplement  (Life  Technologies),  and  1%  penicillin/streptomycin  (Life  
Technologies)  and  cultures  were  grown  until  live  Ca2+  imaging  was  performed  on  in  vitro  (DIV)  
12-­14.  The  animal  care  and  protocol  (16-­6779A)  was  approved  by  Colorado  State  University’s  
Institutional  Animal  Care  and  Use  Committee.    
  
GCaMP  Calcium  Imaging  
DIV4  neurons  plated  on  glass  bottom  dishes  were  transfected  with  either  pGP-­CMV-­
GCaMP6f  (a  gift  from  Douglas  Kim,  Addgene  plasmid  #40755;;  
http://n2t.net/addgene:40755;;RRID:Addgene_40755)  (55)  for  imaging  of  hippocampal  pyramidal  
excitatory  neurons or  pAAV-­mDLX-­GCaMP6f-­Fishell-­2  (a  gift  from  Gordon  Fishell,  Addgene  
plasmid  #  83899;;  http://n2t.net/addgene:83899;;  RRID:Addgene_83899)  (56)  for  imaging  of  
interneurons  using  Lipofectamine  2000  (Life  Technologies)  and  following  the  manufacturer’s  
instructions.  After  transfection,  the  neurons  were  grown  in  Neurobasal  Medium  without  phenol  
red  (Life  Technologies)  with  B27  supplement  (Life  Technologies),  0.5mM  Glutamax  (Life  
Technologies)  and  1%  penicillin/streptomycin  (Life  Technologies)  for  8-­10  days  and  during  
imaging.  Transfection  efficiency  was  about  2%  and  near  low  to  no  signs  of  toxicity  including  
swollen  neurites  and  cell  body  shrinkage.  Imaging  on  an  Olympus  IX73  microscope  was  
performed  when  glass  bottom  dishes  were  mounted  on  a  temperature-­controlled  stage  at  37oC  
with  5%  CO2  in  a  Tokai-­Hit  heating  stage  with  digital  temperature  and  humidity  controller.  Ca
2+  
activity  in  the  cell  body  (excluding  dendrites)  was  measured.  A  total  of  100  images  per  neuron  
were  captured  with  a  10  ms  exposure  time  and  a  500  ms  interval  using  a  60x  immersive  
objective  (NA=1.42).  15  to  30  neurons  per  glass  bottom  were  imaged.  Fmin  was  determined  as  
the  minimum  fluorescence  value,  and  total  calcium  activity  was  determined  for  each  neuron  by  





   Cultured  hippocampal  neurons  transfected  with  GCaMP6f  and  HA-­tagged  WT  δ-­catenin  
were  fixed  in  4%  paraformaldehyde  in  PBS  for  30  min  after  live  Ca2+  imaging,  blocked  in  5%  
normal  goat  serum  (NGS)  and  0.3%  Triton-­X  for  30  min,  and  then  incubated  overnight  with  an  
anti-­HA  antibody  (Santa  Cruz  Biotechnology,  1:1000)  to  identify  δ-­catenin  transfected  neurons.  
After  3  washes  with  in  PBS  for  10  min  each,  cells  were  incubated  with  Alexa-­Flour-­647  
conjugated  secondary  antibody  (Life  Technologies  1:500)  in  0.3%  Triton-­X  for  2  hrs,  washed,  
and  mounted  in  FluoroGel  Para  Phenylenediamine  Anti  Fading  Mounting  Medium  (Electron  
Microscopy  Sciences).  Neurons  were  imaged  with  a  60x  immersive  objective  (NA=1.42)  using  
an  Olympus  IX73  microscope.  
 
Statistics    
The  statistical  comparisons  were  performed  using  GraphPad  Prism6  software.  For  single  
comparisons,  unpaired  two-­tailed  Student  t-­tests  were  used.  For  multiple  comparisons,  one-­way  
analysis  of  variance  (ANOVA)  with  Fisher’s  Least  Significance  Difference  (LSD)  test  and  two-­
way  ANOVA  with  Fisher’s  LSD  test  were  used  in  order  to  determine  statistical  significance.  
Results  were  represented  as  ±  standard  mean  error  (SEM)  and  p  value  <0.05  was  defined  as  
statistically  significant.  
  






G34S  δ-­catenin  mutation  promotes  GSK3β-­mediated  premature  degradation  
We  examined  whether  the  G34S  δ-­catenin  mutation  promoted  GSK3β-­mediated  
premature  δ-­catenin  degradation.  To  compare  WT  δ-­catenin  to  G34S  δ-­catenin  protein  levels,  
equal  amounts  of  plasmids  expressing  WT  δ-­catenin  or  G34S  δ-­catenin  were  transfected  into  
HEK293  cells  lacking  endogenous  δ-­catenin  expression  with  either  25nM  control  (CTRL)  siRNA  
or  25nM  GSK3β  siRNA,  and  δ-­catenin  expression  levels  were  measured  by  immunoblots.  There  
was  significantly  lower  δ-­catenin  expression  found  in  G34S  δ-­catenin  transfected  cells  
compared  to  WT  δ-­catenin  transfected  cells  (Fig.  3a  and  3b).  When  cells  were  treated  with  
GSK3β  siRNA,  we  found  significantly  lower  GSK3β  protein  levels  when  compared  to  CTRL  
siRNA  treatment,  confirming  that  GSK3β  siRNA  treatment  was  sufficient  to  reduce  GSK3β  
activity  (Fig.  3a  and  3c).  Importantly,  lower  δ-­catenin  expression  levels  in  G34S  δ-­catenin  
transfected  cells  were  reversed  with  GSK3β  siRNA  treatment,  but  no  change  in  δ-­catenin  
protein  levels  found  in  WT  δ-­catenin  transfected  cells  treated  with  GSK3β  siRNA  compared  to  
CTRL  siRNA  treatment  (Fig.  3a  and  3b),  possibly  due  to  a  ceiling  effect  of  WT  δ-­catenin  
overexpression  in  HEK293  cells.  Thus,  inhibition  of  GSK3β  activity  was  sufficient  to  rescue  the  
reduction  of  δ-­catenin  protein  levels  in  G34S  δ-­catenin-­expressed  cells,  suggesting  G34S  δ-­
catenin  is  a  loss-­of-­function  mutation.    
As  GSK3β-­mediated  phosphorylation  of  G34S  δ-­catenin  could  induce  proteasome-­
mediated  δ-­catenin  degradation,  we  determined  if  G34S  δ-­catenin  underwent  premature  
proteasomal  degradation  by  inhibiting  the  proteasome.  The  proteasome  inhibitor  MG132  (10µM)  
was  incubated  in  WT  δ-­catenin  or  G34S  δ-­catenin  transfected  HEK293  cells  for  16  hrs.  A  
significant  increase  in  δ-­catenin  expression  levels  were  found  in  G34S  transfected  cells  with  
MG132  treatment  compared  to  WT  δ-­catenin  transfected  cells  with  MG132  treatment  (Fig.  4a  
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and  4b).  This  finding  suggests  proteosomal  degradation  is  important  for  reduction  of  G34S  δ-­
catenin  expression,  which  may  result  in  loss  of  δ-­catenin  function  in  ASD.  
  
Figure  3.  G34S  δ-­catenin  induces  GSK3β-­mediated  premature  degradation.  a)  
Representative  immunoblots  of  HEK293  cell  lysates  transfected  with  1µg  of  WT  or  G34S  δ-­
catenin  and  treated  with  CTRL  siRNA  or  GSK3β  siRNA.  b)  Summary  graph  of  average  
normalized  δ-­catenin  levels  showing  significantly  lower  G34S  δ-­catenin  levels  are  rescued  by  
siRNA-­mediated  GSK3β  knockdown  (n=8  experiments,  *p<0.05,  Two-­way  ANOVA,  Fisher’s  
LSD  Test).  c)  Summary  graph  of  normalized  GSK3β  intensity  showing  GSK3b  siRNA  is  
sufficient  in  reducing  GSK3b  levels  (n=8  experiments,  ****p<0.0001,  Two-­way-­ANOVA,  
uncorrected  Fisher’s  LSD).  Summary  graphs  are  represented  by  mean  ±  s.e.m.  
  
  
Figure  4.  G34S  δ-­catenin  undergoes  degradation  via  the  proteasome.  a)  Representative  
immunoblots  and  b)  summary  graph  of  average  normalized  δ-­catenin  levels  in  HEK293  cells  
treated  with  proteasome  inhibitor  10µM  MG132  for  16-­18  hrs  showing  blocking  the  proteasome  
significantly  increases  G34S  δ-­catenin  levels  (n=6  experiments,  *p<0.05,  unpaired  two-­tailed  






GSK3β-­mediated  phosphorylation  is  important  for  G34S  δ-­catenin  premature  degradation    
  
Additional  mutations  of  δ-­catenin  at  position  34  were  made  to  elucidate  if  G34S  mutant  
was  phosphorylated  by  GSK3β.    First,  we  substituted  glycine  34  for  alanine  to  make  G34A  δ-­
catenin  mutant  that  was  unable  to  be  phosphorylated  by  GSK3β.  G34A  δ-­catenin  allowed  us  to  
determine  whether  phosphorylation  at  position  34  was  important  for  inducing  premature  
degradation.  Given  that  G34A  δ-­catenin  was  degraded  normally  by  GSK3β  phosphorylation  of  
T1078,  there  was  no  difference  in  δ-­catenin  levels  in  cells  expressing  WT  δ-­catenin  and  G34A  
δ-­catenin  regardless  of  siRNA  treatment  (Fig.  5a  and  5b).  This  suggests  absence  of  additional  
GSK3β-­mediated  phosphorylation  is  incapable  of  reducing  δ-­catenin  levels.  Next,  we  generated  
a  G34D  δ-­catenin  mutant  in  which  glycine  was  substituted  with  a  phospho-­mimetic  aspartate  (D)  
at  position  34.  A  significant  reduction  of  δ-­catenin  levels  in  G34D  δ-­catenin  transfected  cells  was  
found  compared  to  WT  δ-­catenin  transfected  cells  when  CTRL  siRNA  was  treated  (WT  δ-­
catenin  +  CTRL  siRNA,  1.0  and  G34D  δ-­catenin  +  CTRL  siRNA,  0.7602±0.081,  p<0.05)  (Fig.  5a  
and  5b)  as  seen  in  cells  expressing  G34S  δ-­catenin  (Fig.  3a  and  3b).  However,  GSK3β  
knockdown  with  siRNA  was  unable  to  increase  δ-­catenin  expression  levels  in  G34D  δ-­catenin  
transfected  cells  (Fig.  5a  and  5b),  unlike  GSK3β  siRNA  treatment  in  G34S  δ-­catenin  
transfected  cells  (Fig.  3a  and  3b).  This  suggests  the  ASD-­associated  G34S  mutation  provides  
additional  GSK3β-­mediated  phosphorylation  of  δ-­catenin,  which  may  induce  premature  δ-­
catenin  degradation.    
  
G34S  δ-­catenin  exhibits  loss  of  δ-­catenin  function  in  neuronal  activity  
   An  analysis  of  synapse  density  in  hippocampal  excitatory  synapses  revealed  that  the  
G34S  δ-­catenin  mutation  exhibits  loss-­of-­function,  presented  by  inability  to  rescue  δ-­catenin  
KO-­induced  loss  of  synapse  density  (2).  Also,  a  previous  study  showed  that  an  increase  in  δ-­
catenin  protein  levels  was  sufficient  to  elevate  AMPAR  surface  expression  and  synaptic  activity    
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Figure  5.  GSK3β-­mediated  phosphorylation  of  G34S  δ-­catenin  is  important  for  premature  
degradation.  a)  Representative  immunoblots  and  b)  summary  graph  of  average  normalized  δ-­
catenin  levels  in  HEK293  cells  showing  phospho-­mimetic  G34D  δ-­catenin  levels  are  significantly  
lower  than  WT  δ-­catenin,  and  GSK3b  knockdown  by  siRNA  is  unable  to  affect  G34D  δ-­catenin  
levels.  G34A  mutation  has  no  effect  on  δ-­catenin  levels  in  the  presence  or  absence  of  GSK3b  
siRNA.  (n=8  experiments,  *p<0.05  and  **p<0.01,  Two-­way  ANOVA,  uncorrected  Fisher’s  LSD).  
Summary  graphs  are  represented  by  mean  ±  s.e.m.  
  
  
in  cultured  neurons  (46).  Therefore,  we  examined  whether  reduction  of  δ-­catenin  levels  by  the  
G34S  mutation  affected  neuronal  activity  in  hippocampal  excitatory  cells.  As  Ca2+  is  an  
important  second  messenger  that  is  involved  in  neuronal  activity  (57),  a  genetically  encoded  
Ca2+  indicator  GCaMP6f  was  transfected  into  cultured  primary  hippocampal  neurons  to  measure  
total  spontaneous  Ca2+  activity  in  the  cell  body  (55).  Overexpression  of  WT  δ-­catenin  in  
hippocampal  neurons  (Fig.  6)  was  able  to  significantly  increase  Ca2+  activity  compared  to  
control  neurons  (CTRL)  (Fig.  7a,  7b,  7k  and  Table  1),  consistent  with  a  gain-­of-­function  effect  
on  excitatory  synapses  shown  previously  (2).  Notably,  G34S  δ-­catenin  overexpression  was  
unable  to  increase  Ca2+  activity  (Fig.  7c,  7k  and  Table  1),  which  was  also  consistent  with  the  
loss-­of-­function  effects  on  excitatory  synapses  reported  previously  (2).  Therefore,  the  G34S  δ-­
catenin  mutation  did  not  show  the  same  gain-­of-­function  effects  on  neuronal  activity  as  WT  δ-­
catenin,  confirming  a  loss-­of-­function  mutation.  We  also  examined  overexpression  of  G34A  δ-­
catenin  and  G34D  δ-­catenin  effects  on  neuronal  activity  to  determine  if  phosphorylation  of  the  δ-­
catenin  amino  acid  at  position  34  affected  Ca2+  activity.  We  found  overexpression  of  G34A  δ-­
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catenin  was  able  to  significantly  increase  Ca2+  activity  (Fig.  7d,  7k  and  Table  1),  as  seen  in  WT  
δ-­catenin  overexpression.  Overexpression  of  phospho-­mimetic  G34D  δ-­catenin  did  not  
significantly  alter  Ca2+  activity  compared  to  CTRL,  signifying  loss  of  δ-­catenin  function  (Fig.  7e,  
7k  and  Table  1).  This  data  suggests  the  phosphorylation  of  the  G34S  δ-­catenin  ASD-­
associated  mutation  could  play  a  critical  role  in  neuronal  activity.  
  
  
Figure  6.  HA-­tagged  WT  δ-­catenin  and  Ca2+  indicator  GCaMP6f  are  co-­expressed  in  
neurons.  Representative  images  of  cultured  hippocampal  neurons  transfected  with  GCaMP6f  
and  HA-­tagged  WT  δ-­catenin,  showing  that  a  neuron  used  for  measuring  Ca2+  activity  express  
both  δ-­catenin  (Red)  and  GCaMP6f  (Green).  A  bar  indicates  20  μm.  
  
G34S  δ-­catenin-­induced  loss-­of-­function  effects  on  neuronal  activity  is  reversed  by  
pharmacological  inhibition  of  GSK3β  
As  our  previous  data  showed  genetic  inhibition  of  GSK3β  was  able  to  rescue  G34S-­
induced  loss  of  δ-­catenin  function  effects  on  protein  levels  in  HEK293  cells  (Fig.  3a  and  3b),  we  
measured  whether  GSK3β  inhibition  was  also  able  to  reverse  G34S  δ-­catenin-­induced  loss-­of-­  
function  in  neuronal  activity.  As  chronic  changes  of  GSK3β  affect  synaptic  plasticity  (58),  we  
pharmacologically  inhibited  GSK3β  activity  in  cultured  hippocampal  neurons  by  acute  2mM  
lithium  chloride  (LiCl)  treatment  for  16-­19  hrs  instead  of  genetic  GSK3β  siRNA  knockdown.  LiCl  
was  able  to  significantly  increase  in  Ca2+  activity  in  CTRL  neurons  (Fig.  7f,  7k  and  Table  1),  




Figure  7.  G34S  δ-­catenin’s  loss-­of-­function  effects  on  neuronal  activity  is  reversed  by  
pharmacological  inhibition  of  GSK3β.  a-­j)  Representative  traces  of  GCaMP6f  fluorescence  
intensity  and  k)  normalized  average  total  spontaneous  Ca2+  activity  summary  graph  in  cultured  
mouse  hippocampal  neurons  transfected  with  a)  GCaMP6f,  b)  WT  δ-­catenin  and  GCaMP6f,  c)  
G34S  δ-­catenin  and  GCaMP6f,  d)  G34A  δ-­catenin  and  GCaMP6f,  e)  G34D  δ-­catenin  and  
GCaMP6f,  and  f-­j)  treated  with  GSK3β  inhibitor  LiCl  (2mM)  for  16-­19  hrs  in  subsequent  order  
(n=number  of  neurons,  *p<0.05,  **p<0.01  and  ****p<0.0001,  Two-­way  ANOVA,  uncorrected  
Fisher’s  LSD).  G34S  δ-­catenin  exhibits  loss-­of-­function  effects  on  neuronal  Ca2+  activity,  which  
is  mediated  by  GSK3b  activity.  Summary  graphs  are  represented  by  mean  ±  s.e.m.  
  
surface  AMPAR  levels  to  enhance  neuronal  activity  as  shown  in  a  previous  study  (46).  We  
found  LiCl  treatment  in  neurons  overexpressing  WT  δ-­catenin  overexpression  also  had  
significantly  higher  Ca2+  activity  (Fig.  7g,  7k  and  Table  1).  Importantly,  overexpression  of  G34S  
δ-­catenin  with  LiCl  treatment  significantly  increased  Ca2+  activity  compared  with  LiCl  treatment  
on  CTRL  neurons  (Fig.  7h,  7k  and  Table  1).  This  suggests  lowering  GSK3β  activity  had  
significant  effects  on  ASD-­associated  G34S  δ-­catenin.  In  addition,  Ca2+  activity  was  significantly  
increased  in  LiCl-­treated  neurons  overexpressing  G34A  δ-­catenin  than  LiCl-­  treated  CTRL  
neurons  (Fig.  7f,  7i,  7k  and  Table  1).  More  importantly,  LiCl  treatment  had  no  significant  effect  
on  Ca2+  activity  in  neurons  overexpressing  G34D  δ-­catenin  (Fig.  7j,  7k  and  Table  1),  
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Table  1:  Comparison  of  Ca2+  activity  in  the  presence  or  absence  of  lithium  treatment  
  
Treatment   Average  Ca2+  activity  (DF/Fmin)   Statistics  
CTRL  –  No  LiCl   0.99±0.06  
p<0.0001  
CTRL  –  LiCl  treatment   1.64±0.11  
WT  –  No  LiCl   1.43±0.11  
p=0.02  
WT  –  LiCl  treatment   1.87±0.21  
G34S  –  No  LiCl   1.04±0.07  
p<0.0001  
G34S  –  LiCl  treatment   2.02±0.25  
G34A  –  No  LiCl   1.54±0.13  
p=0.02  
G34A  –  LiCl  treatment   2.0±0.17  
G34D  –  No  LiCl   1.23±0.10  
n.s.  p=0.29  
G34D  –  LiCl  treatment   1.44±0.14  
  
  
suggesting  the  mechanism  in  which  G34S  δ-­catenin  induces  loss  of  δ-­catenin  function  can  be  
mediated  by  GSK3β-­induced  phosphorylation.  Overall,  the  G34S  mutation  of  δ-­catenin  provides  
an  additional  GSK3β-­mediated  phosphorylation  site,  which  could  promote  proteasome-­mediated  
δ-­catenin  premature  degradation,  resulting  in  loss-­of-­function  effects  on  neuronal  activity  in  
ASD.  In  addition,  inhibition  of  GSK3β  activity  is  able  to  reverse  G34S-­induced  loss  of  δ-­catenin  
function  
  
The  δ-­catenin  G34S  mutation  has  no  effects  on  neuronal  activity  in  inhibitory  neurons  
Notably,  ASD  has  been  associated  with  a  disrupted  balance  of  synaptic  excitation  and  
inhibition  (E/I  balance)  (59),  in  which  altered  synaptic  development  and  activity  may  contribute  
to  ASD  pathophysiology.  Therefore,  we  measured  Ca2+  activity  in  inhibitory  neurons  to  
determine  if  ASD-­associated  G34S  δ-­catenin  affected  inhibitory  neuronal  activity  and  ultimately  
altered  the  E/I  balance.  To  measure  inhibitory  neuronal  activity,  we  used  GCaMP6f  under  the  
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control  of  the  GABAergic  neuron-­specific  enhancer  of  the  mouse  Dlx  gene  (56),  and  found  that  
both  WT  and  G34S  δ-­catenin  overexpression  were  unable  to  affect  Ca2+  activity  in  interneurons  
(Fig.  8a-­c).  Although  this  suggests  that  δ-­catenin  is  likely  to  affect  mainly  excitatory  neurons,  
but  not  interneurons,  further  studies  are  needed  to  understand  roles  of  δ-­catenin  in  
interneurons.  Furthermore,  there  were  no  significant  changes  in  Ca2+  activity  when  neurons  
overexpressing  WT  or  G34S  δ-­catenin  were  treated  with  LiCl  (Fig.  8d-­f),  suggesting  that  
GSK3β-­mediated  degradation  of  δ-­catenin  plays  critical  roles  in  excitatory  neurons  rather  than  
inhibitory  neurons.  Thus,  G34S  δ-­catenin  may  cause  synaptic  dysfunction  by  altering  neuronal  
activity  in  excitatory  neurons  but  not  inhibitory  neurons,  supporting  the  idea  that  the  E/I  
imbalance  is  associated  with  ASD-­linked  pathophysiology.  
  
Figure  8.  Neuronal  Ca2+  activity  in  inhibitory  neurons  is  unaffected  by  G34S  δ-­catenin  
mutant.  Representative  traces  of  GCaMP6f  under  control  of  mouse  GABAergic  neuron-­specific  
enhancer  and  normalized  average  of  total  spontaneous  Ca2+  activity  summary  graph  in  cultured  
mouse  hippocampal  neurons  transfected  with  a)  mDlx-­GCaMP6f,  b)  WT  δ-­catenin  and  mDlx-­
GCaMP6f,  c)  G34S  δ-­catenin  and  mDlx-­GCaMP6f,  and  d-­f)  treated  with  GSK3β  inhibitor  LiCl  
(2mM)  for  16-­19  hrs  in  subsequent  order  (n=number  of  neurons).  Overexpression  of  WT  δ-­
catenin  and  G34S  δ-­catenin  has  no  effect  in  inhibitory  neuronal  Ca2+  activity  in  the  presence  or  






   Although  ASD-­associated  G34S  mutant  δ-­catenin  was  previously  shown  to  have  the  
inability  to  rescue  loss  of  excitatory  synapse  density  in  hippocampal  neurons  lacking  the  δ-­
catenin  gene  indicating  loss  of  δ-­catenin  function  (2),  the  cellular  mechanisms  of  how  the  G34S  
mutation  causes  loss-­of-­function  in  the  synapse  was  unclear.  In  this  study,  we  demonstrated  
that  G34S  δ-­catenin  was  degraded  prematurely  by  a  GSK3β-­mediated  additional  
phosphorylation  of  δ-­catenin  to  induce  loss-­of-­function,  thus  causing  aberrant  neuronal  function  
in  ASD.  Indeed,  we  found  significantly  lower  G34S  δ-­catenin  levels  compared  to  WT  when  
expressed  in  cells  lacking  endogenous  δ-­catenin,  which  was  rescued  with  either  genetic  GSK3β  
knockdown  (Fig.  3)  or  proteasome  inhibition  (Fig.  4).  Our  analysis  on  neuronal  activity  in  
cultured  mouse  primary  hippocampal  neurons  revealed  overexpression  of  G34S  δ-­catenin  was  
unable  to  show  the  same  increase  in  neuronal  activity  as  overexpression  of  WT,  confirming  loss  
of  δ-­catenin  function,  which  was  reversed  with  pharmacological  inhibition  of  GSK3β  by  lithium  
(Fig.  7  and  Table  1).  In  addition,  we  found  that  δ-­catenin  may  alter  the  E/I  balance,  as  WT  and  
mutant  δ-­catenin  were  unable  to  affect  neuronal  activity  in  inhibitory  neurons  (Fig.  8).  Thus,  we  
have  provided  support  that  loss  of  δ-­catenin  function  associated  with  severe  ASD  is  induced  by  
GSK3β-­mediated  premature  degradation  which  can  be  reversed  by  GSK3β  inhibition.  
   Given  that  we  used  primary  neurons  containing  endogenous  δ-­catenin,  lack  of  gain-­of-­
function  by  G34S  δ-­catenin  was  interpreted  as  loss-­of-­function.  Therefore,  further  studies  are  
needed  to  understand  the  exact  effects  of  G34S  δ-­catenin  on  the  synapse  by  using  acute  
genetic  shRNA  knockdown  of  δ-­catenin  and  re-­expression  of  δ-­catenin  encoding  shRNA-­
resistant  protein  as  shown  previously  (11)  or  δ-­catenin  KO  neurons  (12).  Given  that  
heterozygous  loss  of  the  GSK3β  gene  is  sufficient  to  inhibit  in  vivo  GSK3β  activity  and  mimic  
the  behavioral  and  molecular  effects  of  lithium  (60),  we  will  breed  GSK3β  heterozygous  KO  
mice  (61)  and  δ-­catenin  KO  mice,  which  would  further  clarify  whether  genetic  inhibition  of  
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GSK3β  will  improve  synaptic  efficacy  for  δ-­catenin-­linked  ASD.  In  addition,  an  increase  in  
neuronal  activity  by  reduction  of  GSK3β  activity  is  possibly  due  to  increased  levels  of  δ-­catenin  
and  subsequent  higher  levels  of  δ-­catenin-­associated  synaptic  complex  proteins  including  GRIP  
and  AMPARs.  Hence,  AMPAR  currents  can  be  measured  to  confirm  this  idea.    
We  have  also  proposed  that  the  G34S  mutation  adds  an  additional  GSK3β-­mediated  
phosphorylation  site,  but  have  not  provided  direct  evidence  that  the  serine  residue  at  position  34  
(S34)  is  phosphorylated  (Fig.  2).  Thus,  further  studies  are  needed  to  determine  if  
phosphorylation  occurs  on  the  ASD-­linked  G34S  mutation  by  using  mass  spectrometry  with  a  
peptide  that  contains  the  amino-­terminal  region  of  S34  in  G34S  δ-­catenin.  In  addition,  given  that  
inhibition  of  the  proteasome  is  able  to  significantly  increase  G34S  δ-­catenin  levels,  we  expect  to  
see  significantly  higher  ubiquitination  levels  in  the  G34S  δ-­catenin  compared  to  the  WT  δ-­
catenin  if  degradation  occurs  by  GSK3β  phosphorylation  and  subsequent  ubiquitination.  
Therefore,  immunoprecipitation  of  WT  and  G34S  δ-­catenin  to  measure  ubiquitination  levels  
could  provide  support  for  this  idea.      
Loss  of  δ-­catenin  function  has  also  been  linked  to  Cri-­du-­chat  syndrome  (19)  with  
autistic-­like  behaviors  exhibited  by  40%  of  individuals  with  the  syndrome  (21).  More  specifically,  
the  syndrome  is  caused  by  a  hemizygous  loss  of  the  tip  of  human  chromosome  5,  specifically  
5p15.2  where  δ-­catenin  is  localized  to  (19).  Our  results  confirm  that  G34S  δ-­catenin  is  a  loss-­of-­
function  mutation,  which  affects  neuronal  activity,  suggesting  there  may  be  the  same  
neurobiological  mechanisms  underlying  loss  of  δ-­catenin  function-­induced  autistic-­like  behaviors  
in  Cri-­du-­chat  syndrome.  Interestingly,  the  missing  chromosome  regions  in  Cri-­du-­chat  
syndrome  also  contains  the  telomerase  reverse  transcriptase  (TERT)  gene,  which  plays  a  role  
in  maintaining  telomere  length  (62).  Notably,  mice  that  overexpress  TERT  show  ASD-­
associated  behavior,  including  impaired  sociability  (63).  Therefore,  other  genes  involved  in  Cri-­
du-­chat  syndrome  are  likely  to  contribute  to  ASD-­like  changes.    
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Our  results  have  revealed  the  reduction  of  GSK3β  is  able  to  reverse  mutant  δ-­catenin-­
induced  loss-­of-­function  effects  on  protein  levels  and  neuronal  activity,  but  there  may  be  other  
kinases  regulating  δ-­catenin  besides  GSK3β.  For  example,  a  mass  spectrometry  study  has  
identified  δ-­catenin  as  one  of  possible  substrates  of  c-­Jun  N-­terminal  kinases  (JNK),  a  
serine/threonine  kinase,  in  the  rat  brain  PSD  (64).  A  JNK-­mediated  phosphorylation  of  serine  
447  (S477)  also  targets  δ-­catenin  for  proteasomal  degradation,  leading  to  reduction  of  δ-­catenin  
levels  and  dendritic  branching  (64).  JNK  phosphorylates  the  armadillo  protein  family  member  β-­
catenin  on  residues  S37  and  T41  in  the  amino  terminal  region,  which  are  also  phosphorylated  
by  GSK3β  (65).  Thus,  JNK  may  provide  additional  phosphorylation  of  the  ASD-­linked  G34S  δ-­
catenin  mutation,  resulting  in  premature  degradation  and  loss  of  δ-­catenin  function.  In  addition,  
CKIa  is  responsible  for  the  priming  phosphorylation  on  β-­catenin  residue  S45,  which  triggers  
subsequent  β-­catenin  phosphorylation  by  GSK3β  (30),  and  it  is  unknown  whether  CK1a  plays  a  
role  in  G34S  δ-­catenin  degradation.  Consequently,  further  experiments  are  needed  to  determine  
whether  JNK  inhibition  or  CK1a  inhibition  can  reverse  mutant  δ-­catenin-­induced  loss-­of-­
function.      
Importantly,  the  brain  areas  responsible  for  G34S  mutation-­induced  ASD  have  not  yet  
been  explored.  According  to  the  Alan  Brian  Atlas  (http://portal.brain-­map.org/),  δ-­catenin  is  
expressed  mainly  in  the  cerebral  cortex,  hippocampus,  olfactory  bulb,  and  has  lower  expression  
in  the  thalamus  and  cerebellum  (13).  δ-­catenin  mRNA  is  present  at  high  levels  in  the  
proliferative  ventricular  zone  and  developing  cortical  plate  in  the  developing  neocortex  (6).  δ-­
catenin  also  plays  a  role  in  the  regulation  in  mature  cortical  neuronal  dendritic  complexity  which  
includes  arbor  size,  segment  number,  tip  number  (13).  Additionally,  δ-­catenin  KO  mice  exhibited  
impairment  in  Pavlovian  fear  conditioning,  which  suggests  hippocampal  and  amygdala  defects,  
along  with  other  hippocampal-­dependent  learning  and  memory  deficiencies  (12).  The  
frontotemporal  lobe,  frontoparietal  cortex,  amygdala,  basal  ganglia  and  anterior  cingulate  cortex  
22  
are  believed  to  be  the  brain  regions  that  mediate  ASD-­associated  behaviors  (66,  67).  Thus,  
further  studies  on  brain  regions  affected  by  ASD-­linked  G34S  mutation  are  a  future  need  for  
understanding  δ-­catenin-­linked  ASD  pathophysiology.  We  have  also  found  the  ASD-­associated  
G34S  δ-­catenin  does  not  affect  inhibitory  neuronal  activity,  suggesting  that  E/I  imbalance  is  
likely  to  contribute  to  ASD-­linked  changes.  Currently,  it  is  not  known  whether  δ-­catenin  is  
present  in  inhibitory  neurons,  thus  further  investigation  on  our  findings  that  show  G34S  δ-­
catenin  has  no  effect  on  inhibitory  neurons  is  needed.    
In  conclusion,  our  data  provides  a  novel  cellular  mechanism  for  ASD  in  which  loss  of  δ-­
catenin  function  is  triggered  by  GSK3β-­mediated  premature  degradation,  inducing  neuronal  
dysfunction.  Inhibition  of  GSK3β  activity  may  be  potential  therapeutic  treatment  for  δ-­catenin-­
associated  ASD  patients.    
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